Dasatinib-Induced Bilateral Pleural Effusions.
| Autor: | Rasul TF; Internal Medicine, University of Miami Miller School of Medicine, Miami, USA., Motoa G; Internal Medicine, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, USA., Flowers RC; Internal Medicine, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Apr 07; Vol. 14 (4), pp. e23906. Date of Electronic Publication: 2022 Apr 07 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.23906 |
| Abstrakt: | Fluid accumulation in the form of pleural effusions and ascites may be attributed to a single etiology. Diagnosis depends on a thorough clinical history as well as fluid analysis. We present the case of a 60-year-old man with chronic myeloid leukemia (CML) on dasatinib, recent right-sided ischemic stroke, alcohol-associated liver disease, cocaine and alcohol use disorders in early remission, and hypertension who presented with subacute-onset of bilateral pleural effusions and ascites. Pleural fluid analysis showed an exudative effusion, while ascitic fluid analysis showed a transudative collection. After an extensive workup, the bilateral effusions were attributed to dasatinib therapy, which was also suspected to play an unclear role in the worsening ascites. Although peripheral edema and pleural effusions are well-recognized and common side effects of tyrosine kinase inhibitors (TKIs), this case represents the first description of a patient presenting with bilateral TKI-induced pleural effusions as well as concomitant ascites of unclear origin. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Rasul et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|